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Acute heart failure remains a major challenge for clinicians and
healthcare systems. The number of annual hospitalizations for
acute heart failure is rising due to the aging of the general pop-
ulation and the increasing prevalence of heart failure. Heart fail-
ure is the leading cause of unplanned hospitalizations for patients
older than 65 years in developed countries.1–4 These acute events
impact the natural history of heart failure progression, as demon-
strated by the dramatic increase in the rate of death and rehos-
pitalizations after an acute heart failure episode.5–7 Similarly,
unplanned visits for worsening symptoms requiring intravenous
diuretic treatment are also associated with poor prognosis, with
a greater than four-fold increase in subsequent mortality.8,9 The
available treatment options (primarily diuretics or vasodilators in
normo/hypertensive patients) provide symptomatic relief,1,10 but
no therapies for acute heart failure have been shown to improve
clinical outcomes in prospective, randomized trials. Thus, reducing
morbidity and prolonging survival remain major unmet needs for
patients with acute heart failure.10–12
Acute heart failure is an ideal target for development of new
therapeutic interventions given its high frequency and negative
impact on clinical outcomes. However, substantial investments in
research and development have not yielded proof of efficacy and
safety for any of the therapies tested.
Results of recent mega-trials
in acute heart failure
The goal of improving outcomes for patients with acute heart
failure has fostered an emphasis on mega-trials, designed to enrol
a sufficiently large number of patients to detect improvements in
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.. survival and/or major outcomes (Table 1).13–23 A comprehensive
review of the results of all major trials is beyond the scope
of this paper, but two recent trials involving vasodilators are
discussed, the results from which were unexpected. These two
trials had unique characteristics. First, it was the first time that the
effects of a short-term 48 h drug infusion on long-term mortality,
at 180 days in RELAX-AHF-2 (Efficacy, Safety, and Tolerability
of Serelaxin When Added to Standard Therapy in Acute Heart
Failure trial-2) and until the end of the study in TRUE-AHF (Trial
of Ularitide Efficacy and Safety in Acute Heart Failure), were
assessed as primary endpoint.23,24 Second, both RELAX-AHF-2
and TRUE-AHF required early randomization from the time of
admission to the hospital and had the most accurate criteria as
possible for patient enrolment, including normal to high blood
pressure and clinical and laboratory signs of congestion. Third,
RELAX-AHF-2 was preceded by two trials and a meta-analysis,
showing a reduction in mortality with serelaxin vs. placebo.21,25,26
TRUE-AHF was a randomized, double-blind, parallel-group,
placebo-controlled trial evaluating the effects of a 48 h infusion of
ularitide (15 ng/kg/min) on the short- and long-term clinical course
of patients with acute heart failure enrolled within 12 hours of pre-
sentation. The study had two co-primary endpoints: cardiovascular
mortality during long-term follow-up (median 15months) and the
early clinical course (first 48 h) of the patient, assessed through a
composite endpoint including death, worsening heart failure and
symptom relief.27 A total of 2157 patients were enrolled, and no
benefit was observed for ularitide vs. placebo in either of the
co-primary endpoints.23
RELAX-AHF-2 was a randomized, double-blind, placebo
controlled study that enrolled 6545 patients with acute heart
© 2018 The Authors
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failure [defined as dyspnoea at rest or with minimal exer-
tion, pulmonary congestion on chest radiograph, and B-type
natriuretic peptide (BNP) ≥500 pg/mL or N-terminal proBNP
(NT-proBNP) ≥2000 pg/mL, treated with intravenous furosemide
≥40mg before screening, estimated glomerular filtration rate
30–75mL/min/1.73m2, and systolic blood pressure>125mmHg].
Patients were randomized 1:1 to serelaxin 30𝜇g/kg/day or placebo.
No difference between treatment groups was observed in the
co-primary endpoints of cardiovascular mortality at 180 days after
enrolment (8.7% serelaxin vs. 8.9% placebo, P= 0.39) or worsening
heart failure events during the first 5 days of hospitalization (6.9%
serelaxin vs. 7.7% placebo, P= 0.10).24
These results raise pertinent questions regarding why these and
other acute heart failure trials have not identified beneficial treat-
ment effects for the therapies tested. It is critical to dissect these
trials and understand whether the drugs were truly ineffective or if
characteristics inherent to the acute heart failure population or the
clinical settings and/or if flaws in clinical trial design or execution
may have contributed (Table 1).13–23
Key lessons learned from
completed clinical trials
Heterogeneity across many aspects relevant to acute heart failure
has been proposed as a major factor influencing clinical trial results.
Such heterogeneity may increase differences in the results of
treatment and the lack of significant results.
Heterogeneity in causes
of rehospitalization or death
Mortality and hospitalizations are by far the most important and,
actually, the more frequently assessed clinical endpoints in random-
ized controlled trials. Their importance is obvious. The value of
hospitalizations as a major cause of reduced quality of life and
increased costs for healthcare is also clear. Lastly, these events
are relatively easy to detect and adjudicate. Unfortunately, their
causes and mechanisms may differ substantially.28,29 A large pro-
portion of deaths and hospitalizations may be non-cardiovascular
or, at least, not related to heart failure.30–33 In the OPTIMIZE-HF
(Organized Program to Initiate Lifesaving Treatment in Hospital-
ized Patients with Heart Failure) registry, 42% of patients had
at least one factor that precipitated the hospitalization for acute
heart failure.34 The most common contributors were pneumo-
nia or respiratory condition (15.3%), acute coronary syndrome
or ischaemia (14.7%), arrhythmia (13.5%), and uncontrolled hyper-
tension (10.7%).34 Other important factors include infection, poor
nutrition, or deconditioning.35,36 Social support, education of the
patient and her/his relatives, home monitoring, and increasing
patient adherence to therapy may therefore have a major impact
on decreasing rehospitalizations, even in the absence of any direct
impact on the progression of cardiac dysfunction.37–42
Regarding the mode of death, the European Society of Cardiol-
ogy Heart Failure Long-Term Registry reported that cardiovascular



















































































.. among patients with acute heart failure. A smaller proportion
(13.7%) of deaths was related to non-cardiovascular causes, while
the cause of death was unknown in slightly over a third (34.7%)
of patients.7 This heterogeneity in precipitants of rehospitalization
and mechanisms of death may obscure the treatment effect of an
intervention if the therapy only influences a single mode of death
or cause of hospitalization.43
Heterogeneity in acute heart failure
pathophysiology and clinical phenotypes
It is accepted that multiple pathophysiologic pathways can lead to
acute heart failure.44 Treatment strategies applied to the broad
population of patients with acute heart failure have not yielded
improvements in outcome. This suggests that phenotyping patients
hospitalized for acute heart failure and administering treatments
specific for the phenotype may be a more effective approach.45
However, the optimum criteria for determining phenotype have
not been defined. They may include purely clinical variables44 or
also incorporate more sophisticated strategies (e.g. bioprofiling,
multimarker panels).
Current treatment algorithms always recommend investigation
of potential causes of decompensation, such as acute coronary
syndromes, hypertensive emergencies, arrhythmias, or mechanical
factors (e.g. acute valve regurgitation, septal rupture, aortic dissec-
tion, pulmonary embolism). A treatment targeting specific causes
may dramatically improve symptoms and clinical outcomes.1,10,46
When a specific cause is not present, assessment of clinical signs
is mandatory. These include signs of congestion and/or peripheral
hypoperfusion as well as blood pressure.1,10,47 Additional variables,
such as time since the first diagnosis of heart failure,48 precipitating
factors of the acute episode,34,49 and co-morbidities50–53 also influ-
ence subsequent outcomes and therapeutic choices. For example,
the specific treatment of iron deficiency has been associated with
improved quality of life and reduced hospitalizations in clinical trials
and meta-analyses.53
However, clinical criteria may be insufficient to detect the under-
lying predominant pathophysiology and differentiate long-term
outcomes.6,44
Heterogeneity by geography
Geographical differences have influenced the results of clinical
trials in acute heart failure.7,54–57 Heart failure trials have become
increasingly global in order to achieve the requisite number of
patients and to compensate for lower enrolment rates in many
Western countries, particularly the United States. The criteria for
hospital admission, treatment approaches, and discharge practices
can vary substantially among countries. For example, registry data
indicate that vasodilators are less commonly used in the United
States (9%), whereas they are used more frequently in other parts
of the world (Europe 33–41%, Japan 78%).58 Geographic disparity
in use of inotropes has also been reported (United States 15%,
Europe 22–30%, Japan 19%).58 Length of stay in the hospital for
patients with acute heart failure is much shorter in the United
States compared to Europe, and it is much longer in Japan.58
© 2018 The Authors
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These differences in length of hospitalization across geographically
diverse study centres affect post-discharge outcomes, primarily
early rehospitalization rates, and it can confound the interpretation
of clinical trial results.5,23,54,59–61
Heterogeneity among clinical
investigative sites
Site characteristics may also have a major influence on outcomes.
An analysis from ASCEND-HF (Acute Study of Clinical Effective-
ness of Nesiritide in Decompensated Heart Failure) showed that
high site enrolment rate was associated with a greater likelihood of
patients completing the study protocol. High study centre enrol-
ment was also independently associated with a lower risk of 30-day
death or rehospitalization.62 In some cases, geographic differences
may be explained by differences in execution of study protocols by
investigative sites (e.g. enrolment of ineligible patients, study drug
non-adherence63), rather than to intrinsic differences in patient
populations.
Strategies for future acute heart
failure clinical trials
The most straightforward explanation for the neutral results of
acute heart failure clinical trials completed to date is simply that
the treatments tested were not effective. Taking this view, the trials
accomplished their primary aim, which is to determine whether or
not a drug is more effective than placebo on patient symptoms or,
preferably, outcomes.
However, some evidence casts doubt on this reasoning. First,
the mechanism of action of drugs like serelaxin and ularitide should
favourably impact the pathophysiologic mechanisms of acute heart
failure. Second, all the major prospective, multicentre random-
ized trials were preceded by smaller phase 2 trials that demon-
strated beneficial effects of the investigational drugs,26,64 although
it is acknowledged that phase 2 results can be unstable due to
the relatively small number of patients or events. Specifically,
serelaxin improved multiple endpoints in a first phase IIb trial
(Pre-RELAX),26 and reduced worsening heart failure and cardio-
vascular and all-cause mortality in the RELAX-AHF trial.21
Thus, it is plausible that therapies for acute heart failure that
have ‘failed’ in randomized controlled trials actually have benefi-
cial effects that remained undetected. A variety of factors could
contribute to this inability to identify a treatment effect (if one
exists), including inadequate site selection and monitoring, subop-
timal matching of study drug to patient phenotype, selection of
the wrong time-point to assess study endpoints (e.g. long-term for
short-term administrations).
Site selection and monitoring
Critical processes have been described to achieve optimal site
selection in acute heart failure trials and their in-depth discussion
goes beyond the aims of this article.65 Assessing sites’ interest in



















































































.. and providing sites with adequate resources to hire experienced
clinical research staff are among the key factors that determine the
success of sites in a clinical trial.65 Geographical heterogeneity and
differences in enrolment rates between sites have been variables
influencing the results of the study in some trials but not in
others.62,66,67
Matching drugs to pathophysiology
Treatments shown to be effective for cardiovascular disease are all
targeted to specific mechanisms of disease progression. This has
been the case with acute coronary syndromes where thromboly-
sis and, then, coronary angioplasty dissolve the coronary thrombus,
as well as with chronic heart failure with reduced ejection frac-
tion where we administer treatments targeted to neurohormonal
activation, tachycardia, and left ventricular dyssynchrony. Unfortu-
nately, acute heart failure can originate from many different patho-
physiologic processes and it seems that we cannot address them
satisfactorily, yet.1,46
Better patient phenotyping has been proposed as a solution
to increase the likelihood of a successful trial. Use of multiple
biomarkers may provide more comprehensive characterization of
pathophysiology,68–72 and the role of genomic and proteomic anal-
yses are under investigation.73 A multimarker approach includ-
ing high-sensitivity cardiac troponin, NT-proBNP, soluble ST2, and
growth differentiation factor-15 on top of known prognostic mark-
ers provided the best prediction of 180-day cardiovascular mor-
tality in an analysis of data from RELAX-AHF.72 However, it is
important to recognize that the finding that these markers have a
prognostic value does not necessarily mean that a treatment chang-
ing their levels may have an impact on outcomes.17–19,23,74 Thus,
a better pathophysiological characterization of patients with acute
heart failure is urgently needed.
Timing of endpoint assessment
Long-term endpoints
Clinical trial endpoints have been extensively discussed
elsewhere.28,75 A major hallmark of acute heart failure is its
high mortality and readmission rates. Correspondingly, morbid-
ity and mortality endpoints have been predominantly used in
clinical trials. However, these endpoints can be problematic in
acute heart failure trials. First, in order to achieve the num-
ber of events needed for adequate statistical power, a large
number of patients (i.e. many thousands) must be enrolled and
long-term follow-up is needed, at least 6months.24 The potential
limitations and challenges previously discussed (e.g. inappropri-
ate inclusion of ineligible patients, geographic differences, poor
clinical site performance) are magnified in large trials. Second,
consistent with the recognition that a single pathophysiologic
process does not fully explain heart failure progression in the
setting of an acute event, it seems unlikely that short-term (e.g.
48 h) administration of a drug would have long-term effects on
outcomes.
The most effective therapy for acute episodes of decompensa-
tion seems to be prevention. Treatments effective in chronic heart
© 2018 The Authors
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failure have also reduced heart failure related hospitalizations.1,46 It
remains, however, to be shown whether the initiation of an appro-
priate treatment at the time of discharge, or shortly thereafter,
and its continuation post-discharge may have beneficial effects on
long-term outcomes. Observational data suggest that beta-blocker
use at the time of hospital discharge is associated with better sur-
vival 60–90 days post-discharge.76 A propensity matched analysis
of 19 980 patients with acute heart failure enrolled in the GREAT
network registry showed that patients receiving a beta-blocker at
discharge had a lower 90-day mortality [hazard ratio (HR) 0.56,
95% confidence interval (CI) 0.46–0.69] and 1-year mortality (HR
0.62, 95% CI 0.55–0.71) than untreated patients.77 Similar findings
were reported for 90-day (HR 0.53, 95% CI 0.42–0.66) and 1-year
mortality (HR 0.62, 95% CI 0.53–0.72) in patients discharged
on a renin–angiotensin system inhibitor compared to those not
treated.77 These findings, while observational, are strengthened by
the knowledge that these drug classes have been shown to prolong
survival and reduce hospitalizations in prospective, randomized tri-
als in patients with chronic heart failure with reduced ejection frac-
tion. Thus, optimizing the use of chronic, guideline-recommended
evidence-based therapies before discharge in patients hospitalized
for acute heart failure should be a priority.
Short-term endpoints
Short-term endpoints may be less ambitious but are potentially
more likely to succeed. However, which endpoints are most
suitable is a topic of debate. Biomarkers, specifically natriuretic
peptides, are associated with patient outcomes and have often
been used as surrogates for outcomes. However, the relationship
between the effect of drug therapy on natriuretic peptides and
outcomes has been inconsistent across trials.14,15,78,79
Short-term clinical endpoints may be more attractive. Worsen-
ing heart failure is defined as worsening symptoms requiring reini-
tiation or increasing doses of intravenous treatment or mechan-
ical devices during the hospitalization for heart failure. It occurs
in 4% to 37% of patients hospitalized for heart failure, and it is
associated with higher plasma levels of natriuretic peptides and
troponin, worsening renal function, longer length of the hospital
stay, increased post-discharge hospitalizations, deaths, and higher
healthcare costs post-discharge.25,80,81 Worsening heart failure is
also sensitive to drug treatment.15,21,80,82 However, it is also highly
dependent on the investigator or patient reporting events, as well
as the specific definition used.82 The occurrence of worsening
heart failure events has declined in recent trials, possibly due
to the increased complexity of case report forms and resultant
underreporting.
Length of stay for the initial hospitalization for acute heart fail-
ure may also be reduced with appropriate treatment.21,26 It is
clinically relevant and significantly impacts on the costs of health-
care. However, it also has marked geographical differences and is
strongly influenced by local treatment patterns. Evaluating propor-
tional rather than absolute length of stay may be one approach to
overcome the limitations of regional/cultural differences in length



















































































.. results in substantial variability in large multicentre trials. Further-
more, current treatment (e.g. intravenous diuretics) is generally
effective for symptomatic relief in most patients. Because of this
treatment response, demonstrating additional treatment effects on
symptoms for a new therapy is difficult. Additionally, a new therapy
may not be considered valuable to health systems and payers if the
symptomatic improvement is the same or only marginally greater
than inexpensive standard therapy (i.e. diuretics) without some evi-
dence of other clinical benefit. Signs of congestion are related with
outcomes, and they may persist at the time of discharge.83,84 Thus,
better congestion relief may be a meaningful endpoint, but accurate
assessment tools and validation studies are lacking.
Conclusions
Acute heart failure remains a major challenge for clinical prac-
tice. Current treatment is insufficient as patients continue to
have poor outcomes. Short-term treatment is unlikely to affect
long-term mortality and/or rehospitalization rates. Thus, compos-
ite endpoints based on symptom relief and short-term events
may be better suited to gauge the effects of drug treatment.
Long-term outcomes are more likely to be improved by adherence
to evidence-based therapies for chronic heart failure to prevent
new episodes of decompensation.
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